Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user.
Immunogen sequence: NTVPNLSRVI WVKTPKPGYP SSEEPSSKEV PSCKQELPEP VSSGGKPQKG KRQGSQAKKS EASPAPRPPA SLEVPSAKGQ VAGPKQ
Highest antigen sequence indentity to the following orthologs: Rat - 78%, Mouse - 79%.
FAM193B, also known as IRIZIO, was initially identified as a protein that is upregulated in alveolar rhabdomyosarcoma (ARMS), a type of fast-growing tumor characterized by chromosomal translocations fusing the PAX3 or PAX7 gene with that of FOXO1. It has been suggested that, in addition to the PAX3-FOXO1 gene fusion, disruption of the Rb and p53 pathways is required for full ARMS tumorigenesis. In PAX3-FOXO1-expressing primary mouse fibroblasts that possessed a defective p53 pathway, FAM193B expression enabled the tumorigenic transformation, suggesting that FAM193B may contribute to rhabdomyosarcomagenesis in humans.
仅用于科研。不用于诊断过程。未经明确授权不得转售。